The Board of Directors also stated that it would endeavour to have a final clarification of the Company’s future by the end of 2017. Source: BioSpace

Following FDA priority review, Repatha is the only PCSK9 inhibitor approved to reduce risk of heart attack, stroke and coronary revascularization. Source: BioSpace

A look at two life science companies that are expected to grow more than 67 percent over the next five years. Source: BioSpace

Today, Janssen Biotech announced it had exercised its option to enter into a collaboration deal with Idorsia to jointly develop and market aprocitentan and any derivative compounds. Source: BioSpace

The COO of Seattle Genetics, Eric Dobmeier, is leaving the company to helm Silverback Therapeutics. Source: BioSpace

Gilead will partner with three coordinating centers to lead the corporate giving program of the initiative. Source: BioSpace

Shares of Ultragenyx are sharply climbing this morning after the company announced positive results from its Phase III study of burosumab in adults with XLH. Source: BioSpace

Barring a huge meltdown, the S&P 500 will once again have a double-digit year of gains, and most investors should be looking at their 401(k)s and other accounts with some…

Sanofi terminated an experimental Clostridium difficile vaccine after an Independent Data Monitoring Committee concluded the Phase III trial was unlikely to hit its endpoints. Source: BioSpace

Tudorza, also marketed as Eklira and Bretaris, is available in more than 50 countries. Source: BioSpace